"Two researchers at the National Institutes of Health discovered a new genetic link between the rapid growth of healthy fetuses and the uncontrolled cell division in cancer. The findings shed light on normal development and on the genetic under"...
Advise patients that ADCETRIS can cause a peripheral neuropathy. They should be advised to report to their health care provider any numbness or tingling of the hands or feet or any muscle weakness [see WARNINGS AND PRECAUTIONS].
Advise patients to contact their health care provider if a fever of 100.5°F or greater or other evidence of potential infection such as chills, cough, or pain on urination develops [see WARNINGS AND PRECAUTIONS].
Advise patients to contact their health care provider if they experience signs and symptoms of infusion reactions including fever, chills, rash, or breathing problems within 24 hours of infusion [see WARNINGS AND PRECAUTIONS].
Progressive Multifocal Leukoencephalopathy
Instruct patients receiving ADCETRIS to immediately report if they have any of the following neurological, cognitive, or behavioral signs and symptoms or if anyone close to them notices these signs and symptoms [see BOXED WARNING, WARNINGS AND PRECAUTIONS]:
- changes in mood or usual behavior
- confusion, thinking problems, loss of memory
- changes in vision, speech, or walking
- decreased strength or weakness on one side of the body
Instruct patients to report symptoms that may indicate pulmonary toxicity, including cough or shortness of breath [see WARNINGS AND PRECAUTIONS].
Advise patients to contact their health care provider if they develop severe abdominal pain [see ADVERSE REACTIONS].
Advise patients to contact their health care provider if they develop severe abdominal pain, chills, fever, nausea, vomiting, or diarrhea [see WARNINGS AND PRECAUTIONS].
Females and Males of Reproductive Potential
ADCETRIS can cause fetal harm. Advise women receiving ADCETRIS to avoid pregnancy during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS.
Advise males with female sexual partners of reproductive potential to use effective contraception during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS [see Use in Specific Populations].
Advise patients to report pregnancy immediately [see WARNINGS AND PRECAUTIONS].
Advise patients to avoid breastfeeding while receiving ADCETRIS [see Use In Specific Populations].
Last reviewed on RxList: 4/1/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Adcetris Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.